(Q28538703)

15

Anne-Catherine Bachoud-Lévi

Laurent Cleret de Langavant

0 references

17

Anne-Catherine Bachoud-Lévi

0 references

Clémence Simonin

Clémence Simonin

7

0 references

Christine Tranchant

Christine Tranchant

9

0 references

Jean-Philippe Azulay

8

Jean-Philippe Azulay

0 references

Alexandra Durr

5

Alexandra Durr

0 references

Christophe Verny

3

Christophe Verny

0 references

author name string

Gaëlle Désaméricq

1

0 references

Guillaume Dolbeau

2

0 references

Perrine Charles

4

0 references

Katia Youssov

6

0 references

Cyril Goizet

10

0 references

Philippe Damier

11

0 references

Emmanuel Broussolle

12

0 references

Jean-François Demonet

13

0 references

Graca Morgado

14

0 references

Isabelle Macquin-Mavier

16

0 references

Patrick Maison

Creative Commons Attribution 4.0 International

18

0 references

language of work or name

English

0 references

publication date

2014

0 references

published in

PLOS One

0 references

volume

9

0 references

issue

1

0 references

page(s)

e85430

0 references

copyright license

start time

15 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Therapeutic interventions for symptomatic treatment in Huntington's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Pharmacologic approaches to the treatment of Huntington's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Huntington's disease: from molecular pathogenesis to clinical treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Psychopathology in Verified Huntington's Disease Gene Carriers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Developments in post-marketing comparative effectiveness research

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Pharmacological management of Huntington's disease: an evidence-based review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Huntington's disease: present treatments and future therapeutic modalities

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Short-term effects of olanzapine in Huntington disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Long-term effects of tetrabenazine in hyperkinetic movement disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Characteristics of individuals with Huntington disease in long-term care

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Olanzapine for Huntington's disease: an open label study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Tiapride in 12 Huntington's disease patients

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

A Europe-wide assessment of current medication choices in Huntington's disease

3 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Functional decline in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Risperidone in chorea and psychosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Functional and motor response to low dose olanzapine in Huntington's disease: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085430

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Unified Huntington's disease rating scale: Reliability and consistency

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893200

Systematic reviews: critical links in the great chain of evidence

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24454865